Related Experiment Video
Updated: Jul 13, 2026

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
Published on: April 3, 2026
Outcome after surgical treatment of gastrointestinal stromal tumors
Anne-Géraldine Weber1, Nicolas Jovenin, Denis Lubrano
1Service de Chirurgie Viscérale, Digestive et Endocrinienne, CHU de Reims, avenue du Général Koenig, 51092 Reims Cedex. AGWEBER@chu-reims.fr
Objectives:
The objectives were to determine among gastrointestinal mesenchymal tumors treated surgically in our unit which were gastrointestinal stromal tumors (GISTs) and to describe their characteristic features and prognostic factors.
Methods:
A second histological and immunohistochemical reading was performed for 56 gastrointestinal mesenchymal tumors, treated surgically in the Reims University Hospital between 1990 and 2005 in order to determine which ones were GISTs. A statistical descriptive and analytical analysis of the demographic, pathological, therapeutic and prognostic factors was performed.
Results:
Eighty-seven percent of the tumors were GISTs. The 5-year specific survival rate was 66.8%. The factors of good prognosis were small tumor size, low mitotic count, complete primary tumor resection without tumor effraction, age less than 60 years, absence of mucosal necrosis, ulceration, and invasion. Type of surgical resection had no impact in terms of survival.
Conclusion:
GISTs are the most common mesenchymal tumors of the digestive tract. Even thought treatment with imatinib is currently available, surgery (preferably total resection without effraction) is the mainstay treatment for GISTs.
Related Concept Videos
Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
Peptic Ulcer Disease V: Surgical Management and Nursing Care
Surgical Interventions for Peptic Ulcer Disease